GlassScriptPhysician profile
Jacklyn M Griffin
NPI 1831522267
$5,614.39
in general payments reported to CMS, 2019-2025
43 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $850 · 2022: $2,089 · 2023: $2,130 · 2024: $395 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941 · Education: $375 · Consulting Fee: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.71 |
| Education | $375.16 |
| Consulting Fee | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $780.00 | 2022 | |
| Amgen INC. | $611.29 | 2021-2023 | Lumakras, Vectibix, Xgeva |
| Janssen Biotech, INC. | $486.83 | 2022-2023 | Imbruvica, Rybrevant, Darzalex |
| Daiichi Sankyo INC. | $406.80 | 2022-2023 | Enhertu, Injectafer |
| Becton, Dickinson and Company | $360.00 | 2024 | |
| Genzyme Corporation | $295.24 | 2021-2025 | |
| Astellas Pharma US INC | $172.59 | 2021-2023 | Cresemba, Xospata, Padcev |
| Abbvie INC. | $151.92 | 2022-2025 | |
| G1 Therapeutics, INC. | $140.34 | 2022 | |
| Stemline Therapeutics INC. | $135.03 | 2021-2023 | Orserdu |
| Incyte Corporation | $130.27 | 2022-2023 | Jakafi |
| Merck Sharp & Dohme LLC | $129.58 | 2021-2023 | Keytruda, Lynparza |
| Emd Serono, INC. | $119.42 | 2023 | Bavencio, Tepmetko |
| Novartis Pharmaceuticals Corporation | $110.72 | 2021-2023 | |
| Genentech USA, INC. | $105.31 | 2022-2025 | Tecentriq, Alecensa, Polivy |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $100.79 | 2022-2023 | Verzenio |
| Astrazeneca Pharmaceuticals LP | $98.07 | 2021-2023 | Calquence |
| Sumitomo Pharma America, INC. | $94.15 | 2023 | Orgovyx |
| Sanofi-Aventis U.S. LLC | $93.00 | 2023 | |
| Aveo Pharmaceuticals, INC. | $92.08 | 2021-2023 | Fotivda |
| Gilead Sciences, INC. | $90.00 | 2021-2023 | Trodelvy |
| Seagen INC. | $83.34 | 2021-2023 | Padcev, Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $71.23 | 2022-2023 | Ninlaro, Iclusig |
| Pfizer INC. | $68.50 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $61.57 | 2022-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $61.21 | 2022-2023 | |
| Exelixis INC. | $56.99 | 2022-2023 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $55.97 | 2022 | |
| Celgene Corporation | $50.25 | 2021-2023 | Reblozyl |
| Genmab U.S., INC. | $45.67 | 2024-2025 | Epkinly |
| Servier Pharmaceuticals LLC | $42.79 | 2023 | |
| Pharmacosmos Therapeutics INC. | $38.92 | 2023 | Monoferric |
| Sobi, INC | $38.65 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $37.67 | 2025 | Libtayo |
| Morphosys, US INC. | $30.08 | 2023 | Monjuvi |
| Karyopharm Therapeutics INC. | $25.17 | 2023 | Xpovio |
| Eisai INC. | $24.21 | 2023 | |
| Adaptive Biotechnologies Corporation | $23.66 | 2022 | |
| Glaxosmithkline, LLC. | $23.03 | 2023 | Shingrix |
| Rigel Pharmaceuticals, INC. | $18.89 | 2023 | Tavalisse, Rezlidhia |
| Organon LLC | $18.17 | 2023 | Ontruzant |
| Ipsen Biopharmaceuticals, INC | $17.74 | 2023 | Onivyde, Somatuline Depot |
| Array Biopharma INC | $17.25 | 2023 | Lorbrena, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacklyn Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.